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ABSTRACT 
There are a number of analgesics for post operative pain management. But all the analgesics available have 
side effects and no analgesic can give complete analgesia in the post operative pain management. Therefore 
to search an indigenous drug for post operative pain management this research work was selected. 
Aim: The main object of this work was to search an indigenous drug for post operative pain management. 
Materials & Methods: For this study sixty patients of fistula in ano of either sex were selected of ASA grade 
I & II. Patients of group I were considered as control group & group II were considered as trial group. The 
patients of group I (control group) were given diclofenac sodium (50mg) at 10 PM of preoperative night and 
1 hour before operation orally with an ounce of plain water and primary threading was done under spinal 
anasesthesia. The patients of group II (trial group) were given one capsule of Shigru seed Ghansatva (500 
mg) at 10pm of preoperative night and 1 hour before operation orally with an ounce of plain water and 
primary threading was done under spinal anaesthesia.  
The patients of group I were given diclofenac sodium 50mg orally and the patients of group II were given 
Shigru seed Ghansatva capsule (500 mg) orally when the patients felt pain in the post operative period. 
Result: Shigru seed Ghansatva in post operative pain management showed its Vedanasthapana properties. 
Conclusion: Shigru seed in the form of Ghansatva has Vedanahar (analgesic) and Sothahar (anti-
inflammatory) properties like tablet diclofenac sodium used as premedicants. 
KEYWORDS: Bhagandar, Fistula in ano, Shigru, Post operative pain management. 
INTRODUCTION
The origin of pain has been considered with the 
origin of life. Ayurveda the science of life has given much 
emphasis to the pain and its consequences. And that is why 
at many places, measures to pacify pain and establishment 
of pleasure has been described. References of ancient 
literature spell the scientific knowledge of pain and its 
consequences to our ancient scholars. Pain (Sula) is one of 
the important symptoms of almost all diseases. Even in 
surgical operations without subsiding pain nobody can 
perform operation smoothly. Acharya Susruta mentioned 
the used of medicated wine or Madya before operation to 
relieve pain.[1] 
Pain is an ordinarily complex sensation which is 
difficult to define and equally difficult to measure in an 
accurate, objective manner. It has been defined as the 
sensory appreciation of afferent nociceptive stimulation 
which elicits an automatic component, both are subjected 
to rational interpretation by the patient. 
There are a number of analgesics for post 
operative pain management. But all the analgesics 
available have side effects and no analgesic can give 
complete analgesia in the post operative pain 
management. Therefore, to search an indigenous drug for 
post operative pain management this research work was 
carried out.[2] 
In Ayurvedic literature there is description of 
three words used for denoting pain i.e., Vedana, Shoola & 
Dukha. Pain mainly depends upon the Prakriti of a patient. 
Pain is a pathological symptom predominantly caused by 
Vata. For example in Vataj prakriti individuals pain 
sensation is more prominently manifested. Pain is 
different from individual to individual, time to time & site 
to site.[3] Shigru has Vedanahar and Sothahar properties 
according to Ayurvedic classics. Shigru did not produce 
any significant side effects when used as premedicants.[4] 
AIM: To evaluate Shigru seed in Sangyaharan in post 
operative pain management. 
OBJECTIVE: The main object of this work is to search an 
indigenous drug for post operative pain management. 
MATERIAL AND METHODS 
Place of study: IPD of Govt. Ayurvedic College & Hospital, 
Guwahati. 
Selection of patients: For this study sixty patients of 
Fistula in ano of either sex of age between 18-50 years and 
of ASA grade I & II was selected and was divided into two 
groups -I & II. Patients of group I was considered as 
control I group and group II was considered as trial group 
having 30 (thirty) patients in each group. 
Inclusion criteria 
1. Patients of age group between 18-50 years of either 
sex. 
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2. Those patients of ASA grade I & II. 
Exclusion Criteria 
1. Those who were outside the ASA grade I & II. 
2. Those who were outside the age of 18-50 years. 
3. Those who were pregnant. 
4. Patients suffering from respiratory, cardiac, hepatic 
or renal diseases. 
5. Patients allergic to Aspirin, Diclofenac sodium or 
other prostaglandin synthetase inhibitors. 
6. Patients with the history of bleeding tendency or on 
anticoagulant therapy. 
7. Patients with the history of peptic ulceration. 
Parameters 
Details of parameters used in the study. 
A. Desirable effects 
(i) Analgesia 
(ii) Sedation 
(iii) Allaying of apprehension 
(iv) Lack of excitement 
B. Undesirable effects 
(i) Dizziness 
(ii) Emetic effect 
Subjective Assessment: Assessment of pain by patients (0-10, Visual Analogue scale)  
 
0 1 2 3 4 5 6 7 8 9 10 
0 = No. Pain, 10 = Worst Possible pain.  
Objective Assessment: By doctor on Duty (0-4)  
0 = No discomfort; patient completely at ease. 
1 = Patient drowsiness or asleep. 
2 = Patient staying still, eyes closed and avoiding    
        movement.  
3 = Strained facial expression.  
4 = Patient writhing, sweating and distressed.  
Procedure 
The study was done at IPD of Govt. Ayurvedic 
College & Hospital, Jalukbari. For this study sixty patients 
suffering from Fistula in ano of either sex was selected of 
ASA grade I & II and was divided into two groups. 
The group I was considered as control group and 
group II was considered as trial group. The patients of 
group I (control group) were given diclofenac sodium 
(50mg) at 10 PM of preoperative night and 1 hour before 
operation orally with an ounce of plain water and primary 
threading was done under spinal anaesthesia. The patients 
of group II (trial group) were given one capsule of Shigru 
seed Ghansatva (500 mg) at 10 PM of preoperative night 
and 1 hour before operation orally with an ounce of plain 
water and primary threading was done under spinal 
anesthesia. The patients of group I were given diclofenac 
sodium 50mg orally and the patients of group II were 
given Shigru seed Ghansatva capsule (500 mg) orally when 
the patient felt pain in the post operative period. There 
were 30 (thirty) patients in each group. 
Table 1: Statistical comparison of mean age, weight and height of the patients. Table 2: Statistical comparison of 
MBP (mm Hg) before pre medication (A), after premedication (B) intraoperative (C) and post operative (D) 
Group Age (years) 
Mean ± SD 
Weight (kg) Mean 
±SD 
Height Mean ±SD 
Group I (Control) 43.0667 ± 9.332  56.9000 ± 6.942 168.50 ± 10.5593 
Group II (Trial) 44.300 ± 6.194 57.333 ± 5.64085 172.433 ± 4.6363 
Comparison between 
groups unpaired ‘t’ test 
t-value 0.515 0.283 1.868 
p-value >0.05 >0.05 >0.05 
Remarks  NS NS Ns  
Table 3: Statistical comparison of difference in the mean pulse rate/mm before premedication (A), after 
premedication (B), Intraoperative (C), and post operative period (D) 
Comparison within the groups  Group I (Control) Group II (Trial) Remark  
 t-value p-value Remark   t-value  p-value  
AI vs BI 6.129 <0.05 S AII vs BII 8.421 <0.05 S 
AI vs CI 7.414 <0.05 S AII vs CII 5.8 >0.05 S 
AI vs DI 2.709 >0.05 S AII vs DII 0.066 >0.05 NS 
Table 4: Statistical comparison of mean respiratory rate per minute before pre medication (A) after 
premedication (B) during intraoperative (C) and post operative period 
Comparison within the groups Group I (Control) Group II (Trial) Remark 
 t-value p-value Remark   t-value p-value 
AI vs BI 3.715 <0.05 S AII vs BII 3.090 <0.05 S 
AI vs CI 3.820 >0.05 S AII vs CII 1.108 >0.05 NS 
AI vs DI 1.238 >0.05 NS AII vs DII 0.522 >0.05 NS 
Table 5: Effect on temperature 
Group Mean respiratory rate/min (Mean ± SD) 
Before pre 
medication (A) 
After premedication 
(B) 
Intra operative 
(C) 
Post operative 
(D) 
Group I (Control) AI 
17.226 ± 1.0148 
BI 
17.266 ± 1.466 
CI 
17.2000 ± 1.0305 
DI 
17.133 ± 1.0742 
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Group II(Trial) AII 
17.433 ± 1.655 
BII 
17.433 ± 1.651 
CII 
17.166 ± 1.0199 
DII 
17.433 ± 0.9352 
Comparison between 
groups un paired t-test 
t-value 0.591 0.557 0.126 1.154 
p-value >0.05 >0.05 >0.05 >0.05 
Remark  NS NS NS NS 
Table 6: Effect on oxygen saturation 
Comparison 
between the groups 
Group I (Control) Group II (Trial) Remarks 
t-value p-value Remarks  t-value p-value 
AI vs BI 14.87 <0.05 S AII vs BII 11.27 >0.05 S 
AI vs CI 0.52 >0.05 NS AII vs CII 0.44 >0.05 NS 
AI vs DI 1.45 >0.05 NS AII vs DII 0.19 >0.05 NS 
Table 7: Desirable and undesirable effect 
Symptom Incidence Group I (Control) Group – II (Trial) p-value Remarks 
  No. % No. % Fisher Exact  
Sedation  Present  11 39.3 9 28.1 
P-0.390 NS 
Absent  19 60.7 21 71.9 
Apprehension  Present  6 21.3 3 9.4 
P-0.281 NS 
Absent  24 68.7 27 90.6 
Excitement  Present  10 35.5 5 15.6 
P-0.24 NS 
Absent  20 64.5 25 84.4 
Dizziness  Present  2 7.1 0 0 
P-0.214 NS 
Absent  28 92.9 30 100 
Nausea Present  3 10.3 1 3.1 
P-0.331 NS 
Absent  27 80.7 30 96.9 
Vomiting  Present  1 3.6 1 3.1 P-0.467  
Absent  29 96.4 29 96.9  
Table 8: Surgical time & duration of anaesthesia 
Parameters  Group I (Control) 
(Mean ± SD) 
Group II (Trial) 
(Mean ±SD) 
t-value p-value Remarks 
Total surgical time (min) 19.321 ± 6.6213 20.325 ± 5.298 0.615 >0.05 NS 
Duration of Anaesthesia (min) 184.2851 ± 22.67 183.12 ± 17.67 0.222 >0.05 NS 
Table 9: Post Anaesthetic sequel 
Side 
effects 
Incidence Group I (Control) Group – II (Trial) p-value Remarks 
No. % No. % Between fisher exact  
Sedation  Present 7 25 5 15.6 
P-0.52 NS 
Absent 23 75 25 84.4 
Nausea Present 5 8.1 1 3.1 
P-0.288 NS 
Absent 25 91.9 29 96.9 
Vomiting  Present 2 7.1 0 0 
P-0.24 NS 
Absent 28 92.9 30 100 
Dizzness  Present 4 14.3 0 0 
P-0.242 NS 
Absent 26 85.7 30 100 
Dyspepsia  Present 0 0 0 0 
0 NS 
Absent 30 100 30 100 
Table 10: Requirement time of 1st dose of analgesic 
Groups Mean ± SD t-value p-value Remakes  
Control group I 223.00 ± 42.30 1.596 >0.05 NS 
Trial group II 239.00 ± 39.65 
DISCUSSION 
The objective of this study was to search an 
indigenous drug for post operative pain management. In 
this study 60 patients were divided into two groups 
consisting of 30 patients in each group. 
All the records of the observations were 
maintained properly. All the observations were observed 
thoroughly. The data is discussed as follows: 
1. Age, weight and height: It was observed that in all the 
groups mean age, weight and height of the patients 
were statistically comparable. 
2. Blood pressure: On the basis of the findings it can be 
attributed that trial drug Shigru exerted effect on CVS 
without producing serious ill effects. 
3. Pulse rate: Observations effect of trial drug Shigru on 
pulse rate during the course of the study support the 
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view of our ancient scholars i.e. Kapha pitta samak 
properties. 
4. Respiratory rate: Observations proved that there is no 
untoward effect of trial or control drugs on the 
respiratory system. 
5. Body temperature (Axillary): It was observed that the 
trial drug Shigru controlled the rise of body 
temperature unlike tab dicolfenac sodium, possesses 
analgesic properties supporting the view of Ayurvedic 
reference (Vedanahar). 
6. Oxygen saturation (SpO2): While observing the 
response of both the control drug and trial drug on 
arterial oxygen saturation during full course of study it 
was noted that both the drugs did not exert any 
significant untoward effects. 
7. Desirable and undesirable effects: All desirable effects 
were found and undesirable effects were either absent 
or negligible with Shigru, the trial drug. 
8. Total surgical and anaesthetic time: the total surgical 
and anesthetic duration was identical in both groups 
and statistically insignificant when compared between 
the groups. 
9. Post anaesthetic Sequel: Minimal and in significant. 
10. Requirement time of first dose of analgesic: The 
requirement of post operative analgesia is felt under 
regional anaesthesia when the effect of anaesthetic 
drug was washed out and patients starts feeling pain.  
The observation suggested that the first dose of 
analgesic in patient of group I and group II 
respectively was comparable and insignificant. 
This observation suggested the Vedana sthapan 
properties of Shigru mentioned in text of Ayurveda. 
CONCLUSION 
 On the basis of the observations made on patients 
operated (primary threading) under lumbar 
subarachnoid block, this can be concluded that 
 The trial drug Shigru in the form of Ghansatva has 
Vedanahara (analgesic) and Sothahar (anti 
inflammatory) properties like tablet Diclofenac 
sodium used as prernedicants. 
 Shigru did not produce any significant side effects 
when used as premedicants. 
 No significant changes were observed in mean blood 
pressure, pulse rate, respiratory rate, temperature 
and oxygen saturation during the whole course of 
the clinical study. 
 The trial drug Shigru in the form of Ghansatva is 
almost equally effective comparison to control drug 
diclofenac sodium (50mg). 
 Further a more detailed study on a large number of 
samples is required to evaluate analgesic and anti-
inflammatory properties and unfold other 
properties of trial drug used as premedicants. 
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